Technologies
This technology combines anti-PD-1 antibodies with epigenetic modifiers to overcome resistance and improve therapeutic outcomes in lymphoma treatment.
Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive malignancy that is frequently associated with amplification of chromosome 9p24.1 in up to 75% of patients. This genetic alteration drives overexpression of PD-L1, PD-L2, and JAK2, altering the cell’s epigenetic landscape. As a result, PMBCL shows limited responsiveness to immune checkpoint blockade. Epigenetic therapies alone have also failed to deliver meaningful clinical benefits. These limitations highlight a critical need for alternative strategies that can more effectively target the underlying epigenetic and immune resistance mechanisms of PMBCL.
The technology is a dual-targeted approach for the treatment of primary mediastinal B-cell lymphoma (PMBCL). The conjunction of epigenetic reprogramming agents with immune checkpoint inhibitors like anti-PD-1 antibodies shows synergistic effects, increasing tumor immunogenicity and reducing resistance. This approach reverses epigenetic silencing, reconditions the tumor microenvironment, and amplifies the effectiveness of existing immune checkpoint therapies. The technology offers a promising avenue to overcome immune escape mechanisms in PMBCL, holding the potential for significantly improved outcomes in patients.
This technology has been validated in vivo using mouse models.
Patent Pending
IR CU24177
Licensing Contact: Kristin Neuman